Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin + paclitaxel + gemcitabine versus Avastin + paclitaxel in first-line HER2-negative metastatic breast cancer
2008-007057-12Phase 2Terminated
- Sponsor
- Roche
- Start
- Jun 2009
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Avastin + paclitaxel + gemcitabine with Avastin + paclitaxel (2 arms). Primary endpoint: Objective response rate. Started Jun 2009; status: terminated.
02
Drugs
bevacizumabpaclitaxelgemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-007057-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007057-12.